ICCM Logo

IceCure Medical Ltd (ICCM) Stock Forecast & Price Prediction

Live ICCM Stock Price & Analysis

Home โ€บ Stocks โ€บ Israel | NASDAQ | Healthcare | Medical Devices

$1.36

-0.01 (-0.73%)

12 Month Price Forecast For ICCM

$1.36
Current Price
$77.50M
Market Cap
3 Ratings
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to ICCM Price Forecasts

+238.2%
To High Target of $4.60
+120.6%
To Median Target of $3.00
+83.8%
To Low Target of $2.50

ICCM Price Momentum

+6.3%
1 Week Change
+10.6%
1 Month Change
-2.9%
1 Year Change
+23.6%
Year-to-Date Change
-6.2%
From 52W High of $1.45
+183.3%
From 52W Low of $0.48

๐Ÿค” Considering IceCure (ICCM)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 15, 2025 3:32 AM UTC

ICCM Analyst Ratings & Price Targets

Based on our analysis of 5 Wall Street analysts, ICCM has a bullish consensus with a median price target of $3.00 (ranging from $2.50 to $4.60). Currently trading at $1.36, the median forecast implies a 120.6% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.

Conversely, the most conservative target is provided by Yi Chen at HC Wainwright & Co., suggesting a 83.8% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

ICCM Analyst Consensus

3
Buy
0
Hold
0
Sell

ICCM Price Target Range

Low
$2.50
Average
$3.00
High
$4.60
Current: $1.36

Latest ICCM Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for ICCM.

Date Firm Analyst Rating Change Price Target
Nov 27, 2024 HC Wainwright & Co. Yi Chen Buy Reiterates $2.50
Nov 8, 2024 HC Wainwright & Co. Yi Chen Buy Reiterates $2.50
Sep 12, 2024 HC Wainwright & Co. Yi Chen Buy Reiterates $2.50
Aug 21, 2024 HC Wainwright & Co. Yi Chen Buy Maintains $2.50
Jul 2, 2024 HC Wainwright & Co. Yi Chen Buy Reiterates $3.00
Jun 5, 2024 HC Wainwright & Co. Yi Chen Buy Reiterates $3.00
May 29, 2024 HC Wainwright & Co. Yi Chen Buy Reiterates $3.00
Apr 16, 2024 HC Wainwright & Co. Yi Chen Buy Reiterates $3.00
Apr 4, 2024 HC Wainwright & Co. Yi Chen Buy Reiterates $3.00
Mar 20, 2024 HC Wainwright & Co. Yi Chen Buy Reiterates $3.00
Mar 20, 2024 Alliance Global Partners Ben Haynor Buy Maintains $2.90
Mar 5, 2024 HC Wainwright & Co. Yi Chen Buy Reiterates $3.00
Nov 29, 2023 HC Wainwright & Co. Yi Chen Buy Reiterates $3.00
Sep 6, 2023 HC Wainwright & Co. Yi Chen Buy Reiterates $3.00
Aug 15, 2023 Alliance Global Partners Ben Haynor Buy Maintains $4.00
Aug 15, 2023 HC Wainwright & Co. Yi Chen Buy Reiterates $3.00
Jul 25, 2023 HC Wainwright & Co. Yi Chen Buy Reiterates $3.00
Jun 1, 2023 HC Wainwright & Co. Yi Chen Buy Reiterates $3.00
May 23, 2023 HC Wainwright & Co. Yi Chen Buy Reiterates $3.00
Mar 28, 2023 HC Wainwright & Co. Yi Chen Buy Reiterates $3.00

Stocks Similar to IceCure Medical Ltd

The following stocks are similar to IceCure based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

IceCure Medical Ltd (ICCM) Financial Data

IceCure Medical Ltd has a market capitalization of $77.50M with a P/E ratio of -4.3x. The company generates $3.34M in trailing twelve-month revenue with a 40.3% profit margin.

Revenue growth is +7.9% quarter-over-quarter, while maintaining an operating margin of -319.3% and return on equity of -94.2%.

Valuation Metrics

Market Cap $77.50M
Enterprise Value $28.55M
P/E Ratio -4.3x
PEG Ratio -5.5x
Price/Sales 23.2x

Growth & Margins

Revenue Growth (YoY) +7.9%
Gross Margin +35.5%
Operating Margin -319.3%
Net Margin +40.3%
EPS Growth +102.4%

Financial Health

Cash/Price Ratio +15.5%
Current Ratio 3.0x
Debt/Equity 4.9x
ROE -94.2%
ROA -47.4%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

IceCure Medical Ltd logo

IceCure Medical Ltd (ICCM) Company Overview

About IceCure Medical Ltd

What They Do

Develops cryoablation systems for tumor treatment.

Business Model

IceCure Medical Ltd generates revenue through the sale of its proprietary cryoablation systems and associated disposable products. Their offerings include various systems tailored for different medical specialties, allowing them to cater to a broad market including oncology and urology.

Additional Information

Founded in 2006 and based in Caesarea, Israel, IceCure is positioned within the growing medical device sector, focusing on innovative technologies for tumor ablation. Their diverse product range, including the ProSense and IceSense3 systems, enhances their market potential across multiple healthcare fields.

Company Information

Sector

Healthcare

Industry

Medical Devices

Employees

71

CEO

Mr. Eyal Shamir

Country

Israel

IPO Year

2011

IceCure Medical Ltd (ICCM) Latest News & Analysis

ICCM stock latest news image
Quick Summary

IceCure Medical Ltd. presented two studies on ProSenseยฎ cryoablation for breast cancer, winning an award. FDA decision on market authorization expected in Q1 2025.

Why It Matters

Positive study results and FDA market authorization expectations for ProSenseยฎ could boost IceCure Medical's stock value and market position in breast cancer treatment.

Source: PRNewsWire
Market Sentiment: Neutral
ICCM stock latest news image
Quick Summary

IceCure Medical has filed for regulatory approval of its ProSenseยฎ Cryoablation System in China, where its IceSense3 system is already approved.

Why It Matters

Approval in China could significantly boost IceCure Medical's market potential and revenues, enhancing investor confidence and possibly increasing stock value.

Source: PRNewsWire
Market Sentiment: Neutral
ICCM stock latest news image
Quick Summary

ProSenseยฎ sales rise, indicating increased adoption of its cryoablation for breast tumors. FDA market authorization decision for early-stage breast cancer expected Q1 2025.

Why It Matters

Rising ProSenseยฎ sales indicate strong market demand and potential growth. FDA approval in early 2025 could significantly enhance revenue and market position, impacting investor sentiment positively.

Source: PRNewsWire
Market Sentiment: Neutral
ICCM stock latest news image
Quick Summary

IceCure Medical Ltd. (NASDAQ: ICCM) announced it has regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the exchange.

Why It Matters

IceCure Medical's compliance with Nasdaq's minimum bid price requirement signals stability and may boost investor confidence, potentially leading to increased share value and trading activity.

Source: PRNewsWire
Market Sentiment: Neutral
ICCM stock latest news image
Quick Summary

IceCure Medical Ltd. announced it received an Intention to Grant Notice from the European Patent Office for its innovative cryogenic connector technology, enhancing safety in cryoablation procedures.

Why It Matters

The patent notice enhances IceCure's competitive position, potentially leading to market exclusivity, increased revenue, and greater investor confidence in its innovative cryoablation technology.

Source: PRNewsWire
Market Sentiment: Neutral
ICCM stock latest news image
Quick Summary

IceCure Medical's ProSenseยฎ cryoablation for early-stage low-risk breast cancer received a favorable FDA Advisory Panel vote. FDA decision expected Q1 2025.

Why It Matters

Positive FDA panel vote for IceCure's ProSenseยฎ could lead to market authorization, potentially increasing demand and stock value for IceCure Medical as a viable cancer treatment option.

Source: PRNewsWire
Market Sentiment: Neutral

Frequently Asked Questions About ICCM Stock

What is IceCure Medical Ltd's (ICCM) stock forecast for 2025?

Based on our analysis of 5 Wall Street analysts, IceCure Medical Ltd (ICCM) has a median price target of $3.00. The highest price target is $4.60 and the lowest is $2.50.

Is ICCM stock a good investment in 2025?

According to current analyst ratings, ICCM has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.36. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for ICCM stock?

Wall Street analysts predict ICCM stock could reach $3.00 in the next 12 months. This represents a 120.6% increase from the current price of $1.36. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is IceCure Medical Ltd's business model?

IceCure Medical Ltd generates revenue through the sale of its proprietary cryoablation systems and associated disposable products. Their offerings include various systems tailored for different medical specialties, allowing them to cater to a broad market including oncology and urology.

What is the highest forecasted price for ICCM IceCure Medical Ltd?

The highest price target for ICCM is $4.60 from at , which represents a 238.2% increase from the current price of $1.36.

What is the lowest forecasted price for ICCM IceCure Medical Ltd?

The lowest price target for ICCM is $2.50 from Yi Chen at HC Wainwright & Co., which represents a 83.8% increase from the current price of $1.36.

What is the overall ICCM consensus from analysts for IceCure Medical Ltd?

The overall analyst consensus for ICCM is bullish. Out of 5 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $3.00.

How accurate are ICCM stock price projections?

Stock price projections, including those for IceCure Medical Ltd, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.